A detailed history of Commonwealth Equity Services, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 10,250 shares of SUPN stock, worth $364,592. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,250
Previous 10,195 0.54%
Holding current value
$364,592
Previous $273,000 17.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$25.77 - $35.16 $1,417 - $1,933
55 Added 0.54%
10,250 $320,000
Q2 2024

Jul 31, 2024

BUY
$25.99 - $33.85 $9,096 - $11,847
350 Added 3.56%
10,195 $273,000
Q1 2024

Apr 29, 2024

SELL
$27.11 - $35.17 $5,015 - $6,506
-185 Reduced 1.84%
9,845 $336,000
Q4 2023

Feb 06, 2024

BUY
$22.72 - $29.68 $8,679 - $11,337
382 Added 3.96%
10,030 $290,000
Q3 2023

Oct 23, 2023

BUY
$27.57 - $32.91 $5,431 - $6,483
197 Added 2.08%
9,648 $266,000
Q2 2023

Aug 10, 2023

BUY
$29.91 - $38.73 $16,450 - $21,301
550 Added 6.18%
9,451 $284,000
Q1 2023

May 11, 2023

BUY
$34.93 - $42.03 $6,986 - $8,406
200 Added 2.3%
8,901 $322,000
Q4 2022

Feb 07, 2023

SELL
$31.09 - $37.88 $47,194 - $57,501
-1,518 Reduced 14.85%
8,701 $310,000
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $11,084 - $13,632
-385 Reduced 3.63%
10,219 $345,000
Q2 2022

Jul 19, 2022

BUY
$25.33 - $34.25 $4,584 - $6,199
181 Added 1.74%
10,604 $306,000
Q1 2022

May 04, 2022

SELL
$28.51 - $32.9 $8,153 - $9,409
-286 Reduced 2.67%
10,423 $336,000
Q4 2021

Jan 31, 2022

SELL
$26.37 - $34.22 $17,694 - $22,961
-671 Reduced 5.9%
10,709 $312,000
Q3 2021

Oct 29, 2021

BUY
$23.54 - $31.39 $33,897 - $45,201
1,440 Added 14.49%
11,380 $303,000
Q2 2021

Aug 11, 2021

BUY
$26.72 - $33.19 $9,672 - $12,014
362 Added 3.78%
9,940 $306,000
Q4 2020

Feb 11, 2021

BUY
$17.7 - $25.81 $169,530 - $247,208
9,578 New
9,578 $240,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.